ONE-WAYDated event · through FY2023
Establishment of a regenerative medicine R&D joint venture with Sysmex
An initiative to establish AlliedCel Co., Ltd., a joint venture with Sysmex Corporation, and advance the research and development of regenerative medicine products. The company will be jointly operated as an equity-method affiliate in which the parties hold a 50.0% voting interest.
Companies2How many companies write about this.
Threads2One company can carry more than one thread here.
PeriodFY2023-Q3 →Last written FY2023
Directionhelps2 helps · 0 hurts · 0 flat